Literature DB >> 15169924

PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5.

E G Schuetz1, M V Relling, S Kishi, W Yang, S Das, P Chen, E H Cook, G L Rosner, C H Pui, J G Blanco, M J Edick, M L Hancock, N J Winick, T Dervieux, M D Amylon, R O Bash, F G Behm, B M Camitta, S C Raimondi, B C Goh, S C Lee, L Z Wang, L Fan, J Y Guo, J Lamba, R Lim, H L Lim, A B Ong, H S Lee, P Kuehl, J Zhang, Y Lin, M Assem, J Schuetz, P B Watkins, A Daly, S A Wrighton, S D Hall, P Maurel, C Brimer, K Yasuda, R Venkataramanan, S Strom, K Thummel, M S Boguski.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15169924     DOI: 10.1124/pr.56.2.1

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


× No keyword cloud information.
  10 in total

1.  Mapping genes that predict treatment outcome in admixed populations.

Authors:  T M Baye; R A Wilke
Journal:  Pharmacogenomics J       Date:  2010-10-05       Impact factor: 3.550

Review 2.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

3.  Genome-wide association study identifies the common variants in CYP3A4 and CYP3A5 responsible for variation in tacrolimus trough concentration in Caucasian kidney transplant recipients.

Authors:  W S Oetting; B Wu; D P Schladt; W Guan; R P Remmel; R B Mannon; A J Matas; A K Israni; P A Jacobson
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

Review 4.  Bioinformatics and variability in drug response: a protein structural perspective.

Authors:  Jennifer L Lahti; Grace W Tang; Emidio Capriotti; Tianyun Liu; Russ B Altman
Journal:  J R Soc Interface       Date:  2012-05-02       Impact factor: 4.118

5.  Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.

Authors:  H-R He; J-Y Sun; X-D Ren; T-T Wang; Y-J Zhai; S-Y Chen; Y-L Dong; J Lu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-12-17       Impact factor: 3.267

Review 6.  Pharmacogenetic basis for therapeutic optimization in Alzheimer's disease.

Authors:  Ramón Cacabelos
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

7.  ABCB1 transporter and Toll-like receptor 4 in trabecular meshwork cells.

Authors:  Algis Grybauskas; Tomoyo Koga; Paulius V Kuprys; Michael Nolan; Ryan McCarty; Loyal Walker; Kelsey A Green; William M Norkett; Beatrice Y J T Yue; Paul A Knepper
Journal:  Mol Vis       Date:  2015-03-05       Impact factor: 2.367

8.  Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer.

Authors:  Priyatham Gorjala; Rick A Kittles; Oscar B Goodman; Ranjana Mitra
Journal:  Cancers (Basel)       Date:  2020-04-17       Impact factor: 6.639

9.  CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents.

Authors:  Ewa Emich-Widera; Wirginia Likus; Beata Kazek; Paweł Niemiec; Anna Balcerzyk; Aleksander L Sieroń; Iwona Zak
Journal:  Biomed Res Int       Date:  2013-08-01       Impact factor: 3.411

10.  Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.

Authors:  Sumonrat Chuwongwattana; Thawinee Jantararoungtong; Santirat Prommas; Sadeep Medhasi; Apichaya Puangpetch; Chonlaphat Sukasem
Journal:  Pharmacol Res Perspect       Date:  2020-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.